Skip to content

PTHS PTHS Royalty obligation extinguishment

Royalty obligation extinguishment at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$407.18M-12.7%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$8.47M+41.8%
AstroNova, Inc. logo
AstroNova, Inc.ALOT
$160K-83.7%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$210.43M-11.9%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$8.47M+41.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$871.19M+75.2%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:RoyaltyObligationExtinguishment.

The official record: PTHS’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's royalty obligation extinguishment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's royalty obligation extinguishment?
PTHS (PTHS) reported royalty obligation extinguishment of $92.25K in Q4 2025.
What does royalty obligation extinguishment mean?
Captures the non-cash or cash-settled reduction of long-term royalty liabilities owed to third parties. Monitoring this helps investors understand the company's efforts to simplify its capital structure and reduce future revenue-sharing burdens.